Spinal cord stimulation (SCS) in treatment of chronic, intractable truncal, and axial pain has been conducted for over 50 years (1). Improvement in stimulator technology is thought to have led to resurgence in use since 2005, when positive randomized control trials showed efficacy in treatment of patients with failed back surgery syndrome (FBSS) (2–4). Axial pain is nociceptive, or neuropathic pain is felt to be secondary to a spinal abnormality that does not have a radicular pattern and includes some forms of FBSS.
Results: There was a significant reduction in mean visual analog scale pain scores in the immediate postoperative phase, (8.61 vs. 2.3, p < 0.001). There were twelve patients who consumed pre-operative opioid, and 75% showed reduction of use with a significantly lower average daily dose (66.8 vs. 26.9 meq/D, p < 0.05). There was a significant reduction in the Oswestry Disability Index during postoperative follow-up visits (p < 0.001). There were no major perioperative or long-term complications from the procedure in follow-up.
Conclusion: The analysis of this cohort suggests successful long-term treatment of a diverse set of patients with PSPS who underwent spinal cord stimulation (SCS) and had meaningful improvement in quality of life and reduction in opioid consumption.
Front. Pain Res., 08 March 2022
Sec. Neuromodulatory Interventions
https://doi.org/10.3389/fpain.2022.847504

